Aiswarya, Ms; Venkateswaramurthy, N.; Sambathkumar, R. published the artcile< Long term effect of obesity treatment: a review>, Computed Properties of 96829-58-2, the main research area is review orlistat lorcaserine phentermine sibutramine rimonabant antiobesity agent obesity.
A review. Obesity is a significant issue that can lead to multiple serious diseases such as osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type II diabetes, cardiac failure, CAD and stroke. When these non-pharmacol. procedures are ineffective, lifestyle modification such as diet and exercise is essential for the prevention and management of obesity, pharmacotherapy may be regarded. The lifestyle and phys. needs of individualized patients should be altered as the original therapy for obesity that concentrated mainly on diet and exercise. Many drugs used in obesity, including orlistat, lorcaserine, phentermine, sibutramine and rimonabant, but long-term use of above drug may cause several life-threatening side effects. Discontinuation of these anti-obesity drugs leads to weight regaining, in which the treatment will be ineffective. Due to enhanced danger of psychiatric disorders and non-fatal myocardial infarction or stroke, permits for rimonabant and sibutramine were withdrawn. Although orlistat is not as efficient in decreasing body weight as other drugs, orlistat is currently the only option available for treating obesity due to its safety for cardiovascular events and beneficial impacts on diabetic control. The aim of this study is to review the long-term effects of obesity treatment.
Research Journal of Pharmaceutical, Biological and Chemical Sciences published new progress about Antiobesity agents. 96829-58-2 belongs to class amides-buliding-blocks, and the molecular formula is C29H53NO5, Computed Properties of 96829-58-2.
Referemce:
Amide – Wikipedia,
Amide – an overview | ScienceDirect Topics